EUVIMEDEUVIMED entdecken
Crossref

Effect of zoledronic acid and pamidronate on renal function

Katherine Koss iD, Melissa Kocek, Tiffany King, Monika Hornung

Journal of Oncology Pharmacy Practice · 2025

DOI: 10.1177/10781552241284635 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Oncology Pharmacy Practice, 2025. Verfasst von Katherine Koss und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Rush University Medical Center; Chicago, IL, USA. Hauptthemen laut MEDLINE: Zoledronic Acid, Acute Kidney Injury, Pamidronate, Bone Density Conservation Agents. Die Arbeit nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is limited data on the effect bisphosphonates have on renal function and the use of bisphosphonates in patients with baseline renal dysfunction.

Objective

The purpose of this study was to determine the incidence of acute kidney injury (AKI) in patients after receiving zoledronic acid or pamidronate.

Methods

A retrospective cohort analysis was conducted of patients who received one dose of a bisphosphonate, either zoledronic acid or pamidronate. The primary objective of this study was to determine the incidence of AKI after bisphosphonate administration. Baseline characteristics were compared, and unadjusted analyses of primary and secondary outcomes were completed using Pearson's chi-square or Fisher's exact test for categorical data and Mann-Whitney U test for continuous data.

Results

There was no difference found in AKI incidence between zoledronic acid and pamidronate (17.1% vs. 15.0%; p = 1.00). Additionally, there was no difference found in AKI incidence between patients with baseline renal dysfunction and those without, (25.0% vs. 15.0%; p = 0.322). There were no differences observed in either corrected calcium within seven days or serum creatinine (SCr) within 30 days returning to baseline after administration, nor were there differences in fever or hypophosphatemia incidences.

Conclusion

Bisphosphonates may be used to treat hypercalcemia of malignancy in patients with and without renal dysfunction. AKI may occur post infusion; however, long-term effects on renal function are infrequent when hydrating patients prior to administration and adhering to the manufacturer's recommended infusion rate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Zoledronic AcidAcute Kidney InjuryPamidronateBone Density Conservation AgentsDiphosphonatesKidneyHumansRetrospective StudiesFemaleMaleAgedMiddle AgedIncidenceCohort StudiesAged, 80 and overCreatinine

Stichwörter der Autor:innen

Hypercalcemiabisphosphonatesendocrinologyrenal failure

Substanzen

Zoledronic AcidPamidronateBone Density Conservation AgentsDiphosphonatesCreatinine

Autor:innen und Institutionen

  • Department of Pharmacy, Rush University Medical Center; Chicago, IL, USA.

ORCID-Profile: Katherine Koss

Zitieren

APA

Koss, K., Kocek, M., King, T., & Hornung, M. (2025). Effect of zoledronic acid and pamidronate on renal function. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/10781552241284635

Vancouver

Koss K, Kocek M, King T, Hornung M. Effect of zoledronic acid and pamidronate on renal function. Journal of Oncology Pharmacy Practice. 2025. doi:10.1177/10781552241284635

BibTeX
@article{Koss2025,
  author = {Koss, Katherine and Kocek, Melissa and King, Tiffany and Hornung, Monika},
  title = {Effect of zoledronic acid and pamidronate on renal function},
  journal = {Journal of Oncology Pharmacy Practice},
  year = {2025},
  doi = {10.1177/10781552241284635}
}
Kostenlos starten →